Outcome of the Board Meeting held on Monday, November 17, 2025 considered and approved the conversion of 7,35,000 warrants into 7,35,000 equity shares of face value of Rs. 10/- (Rupees Ten Only)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Shelter Pharma Ltd, at its meeting on November 17, 2025, approved the conversion of 7,35,000 convertible warrants into an equal number of equity shares of face value Rs. 10 each. The conversion was done by two promoter group members — Shakil Nisarahmed Sabugar (4,50,000 shares) and Mustaqim Nisarahmed Sabugar (2,85,000 shares) — who paid the remaining 75% exercise price of Rs. 31.6875 per share at the original warrant issue price of Rs. 42.25 (including a premium of Rs. 32.25). The total amount paid for conversion is approximately Rs. 2.33 crore. As a result, the company's paid-up equity share capital has risen from Rs. 15.60 crore (1.55 crore shares) to Rs. 16.33 crore (1.63 crore shares).
This is a promoter-driven conversion, which signals insider confidence in the company's prospects. While the total share count increases by about 4.7% (leading to mild dilution for non-promoter shareholders), the fact that promoters are bringing in additional capital to convert their warrants is generally seen as a positive sign. Existing shares will trade pari-passu with the newly issued shares once listed.